General Information of Drug (ID: DMUBEX4)

Drug Name
CAR-T cells targeting MAGE-A4 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMUBEX4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ADP-A2M4 DMRYH3M Synovial sarcoma 2B5A Phase 2 [2]
Afamitresgene autoleucel DM1GR4M Soft tissue sarcoma 2B57 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanoma-associated antigen 4 (MAGEA4) TT9EQUY MAGA4_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
2 Clinical pipeline report, company report or official report of Adaptimmune.
3 Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023 Jan;29(1):104-114.